SCHOTT invests in further melting capacities for pharma glass in India
Investment of 70 million euros will increase capacity by 30 per cent and create 225 new jobs
SCHOTT is investing a total of 70 million euros in the expansion of its Indian tubing site in Jambusar, Gujarat, following several million investments in the last years, a statement from the company said.
“Against the backdrop of the growth trend in the Indian pharmaceutical business and the pandemic, we want to commit to secure the supply of pharma glass,” explains Dr Patrick Markschläger, Executive Vice President, Business Unit Tubing, SCHOTT.
“The increase of over 30 per cent in the facility’s overall Indian production capacity is at the same time a commitment to supporting the government’s vision of India becoming a global pharmaceutical hub,” added Pawan Shukla, Managing Director, SCHOTT Glass India.
The additional tank is scheduled to go into operation at the beginning of 2023, with the second one following a year later. The expansion in Jambusar will create new jobs for around 225 employees and is part of a more than $1 billion strategic investment programme of SCHOTT through 2025, leveraging the global pharma tubing and packaging business.
In India, almost all approved vaccines are packed in Fiolax glass made by SCHOTT. With additional melting tanks and production lines, SCHOTT intends to ensure that this Asian manufacturing hub can adequately supply high-quality pharma glass for the Indian pharma industry and neighboring countries, added the statement.